This page maybe helpful for you to understand the
Post# of 30028
http://mpasearch.co.uk/product-process-formulation-patents
I think the company explained it 2-3 years ago on a share holder call (i.e. "they have too go through us" . If someone wants to dig it up, it would be worth having handy as this question does come almost every time someone patents a method of treatment.
What you'd like to own is Product patent, product claim, composition of matter.
http://inventingpatents.com/composition-matter-claims/
Does Amarantus have that? Yes. Do others companies have composition of matter? I don't know. I didn't to an exhaustive search nor understand if there are different flavors of MANF.
There are people here that are much smarter about patents but I'll give you an analogy.
Let's say Vitamin D didn't exist. Bid deal right? The body makes Vitamin D so having a pill for it isn't of value. But what the hell, you go ahead and get a product patent anyway for composition of matter on Vitamin D. Means that anyone that wants it has to get it from you or license it.
Then you realize not everyone's body makes enough vitamin D especially the closer you get to the poles. And someone else figures out that Vitamin D can cure 10 other issues, but they put a patent on those methods of uses because they did all the research and figured it all out.
So you would think the Vitamin D product patent holder is screwed? Not quite, the more people figure out uses of Vitamin D, the more Vitamin D pills he sells. Or he works with the other people on a royalty.
Now if you are the Vitamin D product patent holder and you can figure out some uses for it to and patent them, that's icing on the cake as you get the whole lion share. Keep in mind the vast majority of that work is done at schools and institutions. That's why the company has collaborated with Buck, Bascom and others that are the #1 institutions in their field.
That's my take on it. I could be totally wrong so best to get the info from the company, but others are welcome to chime in and correct or add to it.
Keep in mind the company has said this many times:
Quote:
Amarantus is the front-runner and primary holder of intellectual property around MANF, and is initially focusing on the development of MANF-based protein therapeutics.